Protagenic Therapeutics, Inc. (PTIX)
PTIX moved a median of 0.00% 30 minutes after news, and +1.75% by the close. How PTIX actually reacts to news — the realized, point-in-time move the market made, measured across 121 labeled events over the last three years with zero look-ahead.
PTIX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 33% | 94 |
| 30-min | 0.00% | 39% | 104 |
| 60-min | 0.00% | 38% | 108 |
| to close | +1.75% | 53% | 115 |
| Middle 50% of PTIX reactions | -3.12% to +1.95% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 121 |
Half of all Protagenic Therapeutics, Inc. news events land between -3.12% and +1.95% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PTIX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PTIX's baseline. Nothing else.
Recent PTIX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Protagenic Therapeutics, For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | — | +30.43% | |
| Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder | Press release | ACCESS Newswire | +0.00% | +50.04% | |
| Form 10-Q Protagenic Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +50.04% | |
| Form 10-K Protagenic Therapeutics, For: Mar 31 | SEC filing · Form 10-K | SEC EDGAR | — | +0.00% | |
| Form NT 10-Q Protagenic Therapeutics, For: Jun 30 | SEC filing · Form NT | SEC EDGAR | — | +0.00% | |
| Form NT 10-K Protagenic Therapeutics, For: Mar 31 | SEC filing · Form NT | SEC EDGAR | — | — | |
| Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model | Press release | ACCESS Newswire | — | — | |
| Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner | Press release | ACCESS Newswire | — | — | |
| Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114 | Press release | ACCESS Newswire | +0.00% | +4.93% | |
| Form 8-K Protagenic Therapeutics, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | — | -24.22% | |
| Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 | Press release | ACCESS Newswire | +0.00% | -1.37% | |
| Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market | Press release | ACCESS Newswire | +0.00% | +8.91% | |
| Form 10-Q Protagenic Therapeutics, For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -6.53% | |
| Form 8-K Protagenic Therapeutics, For: Feb 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +10.94% | |
| Form 8-K Protagenic Therapeutics, For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -7.63% | |
| Form NT 10-Q Protagenic Therapeutics, For: Dec 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | +20.00% | |
| Form 8-K Protagenic Therapeutics, For: Dec 31 | SEC filing · Form 8-K | SEC EDGAR | +0.03% | +76.91% | |
| Results from Phase 1 Multiple-Dose Study of PT00114 | Press release | ACCESS Newswire | +2.58% | +4.52% | |
| Form DEF 14A Protagenic Therapeutics, For: Dec 05 | SEC filing · Form DEF | SEC EDGAR | -1.71% | -5.71% | |
| Form 10-Q Protagenic Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.19% | +11.52% | |
| Form 8-K Protagenic Therapeutics, For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | +4.19% | +11.52% | |
| Form NT 10-Q Protagenic Therapeutics, For: Sep 30 | SEC filing · Form NT | SEC EDGAR | +0.00% | -0.48% | |
| Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study | Press release | ACCESS Newswire | +2.04% | — | |
| Form 8-K Protagenic Therapeutics, For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | +1.90% | -2.84% | |
| Form 8-K Protagenic Therapeutics, For: Oct 28 | SEC filing · Form 8-K | SEC EDGAR | +2.88% | +7.66% | |
| Form 8-K/A Protagenic Therapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | — | +6.98% | |
| Form 10-QT Protagenic Therapeutics, For: Jun 30 | SEC filing · Form 10-QT | SEC EDGAR | -1.75% | +16.49% | |
| Form 8-K/A Protagenic Therapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -0.51% | -7.79% | |
| Form 8-K Protagenic Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +14.52% | +11.08% | |
| Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance | Press release | ACCESS Newswire | +14.52% | +11.08% | |
| Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders | Press release | ACCESS Newswire | +21.37% | +16.71% | |
| Form NT 10-Q Protagenic Therapeutics, For: Jun 30 | SEC filing · Form NT | SEC EDGAR | +0.00% | -6.98% | |
| Form 8-K Protagenic Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -1.08% | +10.43% | |
| Form 8-K Protagenic Therapeutics, For: Jul 18 | SEC filing · Form 8-K | SEC EDGAR | -2.15% | -9.54% | |
| Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates | Press release | GlobeNewswire | -0.36% | +5.28% | |
| Form 8-K Protagenic Therapeutics, For: Jul 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.52% | |
| Form 8-K Protagenic Therapeutics, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.44% | |
| Form 8-K Protagenic Therapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -2.74% | -11.53% | |
| Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity | Press release | ACCESS Newswire | -2.74% | -11.53% | |
| Form 8-K Protagenic Therapeutics, For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -2.33% | -20.56% | |
| Form 8-K Protagenic Therapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -0.68% | +34.22% | |
| Form DEFA14A Protagenic Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -4.37% | -20.92% | |
| Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders | Press release | ACCESS Newswire | -0.68% | +34.22% | |
| PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders | Press release | Business Wire | -10.52% | -0.18% | |
| Form 10-Q Protagenic Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.89% | +2.18% | |
| Form 8-K Protagenic Therapeutics, For: May 02 | SEC filing · Form 8-K | SEC EDGAR | -9.84% | -9.52% | |
| Form 8-K Protagenic Therapeutics, For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -3.12% | +5.91% | |
| Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split | Press release | ACCESS Newswire | -3.12% | +5.91% | |
| Form 8-K Protagenic Therapeutics, For: Apr 18 | SEC filing · Form 8-K | SEC EDGAR | +2.10% | -8.73% | |
| Form 10-K Protagenic Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -6.20% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PTIX section they belong to.
Where else PTIX is measured.
PTIX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ZIVO BIOSCIENCE INC (ZIVO) | 122 | 0.00% | 29% |
| American Shared Hospital Services (AMS) | 121 | 0.00% | 48% |
| Xenetic Biosciences, Inc. (XBIO) | 121 | 0.00% | 38% |
| Avenue Therapeutics, Inc. (ATXI) | 120 | 0.00% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Protagenic Therapeutics, Inc.'s median reaction calculated?
Every labeled PTIX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 121 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of PTIX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PTIX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.